Dennis R. Leahy, MD, shares his POV on the value of making Lp(a) testing universal, not only to inform patients and their clinicians of the high CV risks, but to make way for potential treatments.
The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD.
Using ORION 9, 10, and 11 data, investigators assessed inclisiran in patients with heterozygous familial hypercholesterolemia, ASCVD, or ASCVD risk.
Researchers sought to determine whether financial incentives for statin adherence, a reduction in LDL cholesterol (LDL-C) levels, or both could lower LDL-C.
An online technology was developed to assess whether physicians and potential patients who may benefit from statin therapy would come to the same diagnostic conclusion.
Researchers evaluated the association between baseline LDL-C and treatment with ezetimibe plus statins in post-acute coronary syndrome.
Investigators aimed to determine the association of pre-existing DPP-4is use with COVID-19–related outcomes among patients with T2DM.
Each individual component of the composite outcome was significantly higher among statin users
The risk for recurrent MACE was high among survivors of a first ever acute coronary syndrome with a substantial number of these being fatal; 34.4% had MACE within 1 year and 48.4% in 3 years.
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH.
